Literature DB >> 27989929

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts.

Claudio G Brunstein1, Corey S Cutler2, Todd E DeFor3, Haesook Kim2, Nelli Bejanyan3, Alfred Garfall4, Michael R Verneris3, Yi-Bin Chen5, Erica D Warlick3, Thomas Spitzer5, Jeffrey S Miller3, Joseph H Antin2, Daniel J Weisdorf3, Robert Soiffer2, John E Wagner3, Karen K Ballen5.   

Abstract

We studied the effect of HLA-C matching in 515 patients after double umbilical cord blood (UCB) transplantation. After HLA matching HLA-A, -B, and -DRB1 at the allele level, we scored patients according to number of donor-recipient HLA-C matches at 4 possible loci: 2 from each donor unit, at the allele level. Given a direct interaction between HLA-A, -B, and -DRB1 matching and HLA-C score, we analyzed HLA-C matching in those receiving at least 1 2/6 to 4/6 HLA-matched unit (n = 389) versus those receiving only 5/6 or 6/6-matched units (n = 126). In those with at least 1 2/6 to 4/6 HLA-matched unit, a better HLA-C matching score was associated with significantly lower risk of death of any cause and nonrelapse mortality and better disease-free survival. There was no association with the risk of relapse, acute and chronic graft-versus-host disease, and hematopoietic recovery. In contrast, among patients receiving only allele-level 5/6 or 6/6 HLA-matched UCB units, HLA-C match had no demonstrable effect on any outcome. For patients receiving at least 1 allele-level 2/6 to 4/6 HLA-matched UCB unit, matching at HLA-C reduces nonrelapse mortality and improves survival.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Alternative donor transplantation; Double umbilical cord blood; Human leukocyte antigen

Mesh:

Substances:

Year:  2016        PMID: 27989929      PMCID: PMC5510875          DOI: 10.1016/j.bbmt.2016.10.018

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  16 in total

1.  HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.

Authors:  Ann Woolfrey; John P Klein; Michael Haagenson; Stephen Spellman; Effie Petersdorf; Machteld Oudshoorn; James Gajewski; Gregory A Hale; John Horan; Minoo Battiwalla; Susana R Marino; Michelle Setterholm; Olle Ringden; Carolyn Hurley; Neal Flomenberg; Claudio Anasetti; Marcelo Fernandez-Vina; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-24       Impact factor: 5.742

2.  Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.

Authors:  Corey Cutler; Haesook T Kim; Lixian Sun; Doreen Sese; Brett Glotzbecker; Philippe Armand; John Koreth; Vincent Ho; Edwin Alyea; Karen Ballen; Jerome Ritz; Robert J Soiffer; Edgar Milford; Joseph H Antin
Journal:  Blood       Date:  2011-09-22       Impact factor: 22.113

3.  Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis.

Authors:  Mary Eapen; John P Klein; Guillermo F Sanz; Stephen Spellman; Annalisa Ruggeri; Claudio Anasetti; Maria Brown; Richard E Champlin; Joan Garcia-Lopez; Gareth Hattersely; Gesine Koegler; Mary J Laughlin; Gerard Michel; Samir K Nabhan; Franklin O Smith; Mary M Horowitz; Eliane Gluckman; Vanderson Rocha
Journal:  Lancet Oncol       Date:  2011-10-06       Impact factor: 41.316

4.  Anti-HLA antibodies in double umbilical cord blood transplantation.

Authors:  Claudio G Brunstein; Harriet Noreen; Todd E DeFor; David Maurer; Jeffrey S Miller; John E Wagner
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-03       Impact factor: 5.742

5.  Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.

Authors:  C Cutler; K Stevenson; H T Kim; J Brown; S McDonough; M Herrera; C Reynolds; D Liney; G Kao; V Ho; P Armand; J Koreth; E Alyea; B R Dey; E Attar; T Spitzer; V A Boussiotis; J Ritz; R Soiffer; J H Antin; K Ballen
Journal:  Bone Marrow Transplant       Date:  2010-08-09       Impact factor: 5.483

6.  Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.

Authors:  Claudio G Brunstein; Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; John E Wagner
Journal:  Blood       Date:  2007-06-14       Impact factor: 22.113

7.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

8.  Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity.

Authors:  Claudio G Brunstein; John E Wagner; Daniel J Weisdorf; Sarah Cooley; Harriet Noreen; Juliet N Barker; Todd DeFor; Michael R Verneris; Bruce R Blazar; Jeffrey S Miller
Journal:  Blood       Date:  2009-03-27       Impact factor: 22.113

9.  Factors predicting single-unit predominance after double umbilical cord blood transplantation.

Authors:  P Ramirez; J E Wagner; T E DeFor; B R Blazar; M R Verneris; J S Miller; D H McKenna; D J Weisdorf; P B McGlave; C G Brunstein
Journal:  Bone Marrow Transplant       Date:  2011-09-26       Impact factor: 5.483

10.  KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia.

Authors:  R Willemze; C A Rodrigues; M Labopin; G Sanz; G Michel; G Socié; B Rio; A Sirvent; M Renaud; L Madero; M Mohty; C Ferra; F Garnier; P Loiseau; J Garcia; L Lecchi; G Kögler; Y Beguin; C Navarrete; T Devos; I Ionescu; K Boudjedir; A-L Herr; E Gluckman; V Rocha
Journal:  Leukemia       Date:  2009-01-08       Impact factor: 11.528

View more
  3 in total

1.  Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.

Authors:  Rohtesh S Mehta; Shernan G Holtan; Tao Wang; Michael T Hemmer; Stephen R Spellman; Mukta Arora; Daniel R Couriel; Amin M Alousi; Joseph Pidala; Hisham Abdel-Azim; Vaibhav Agrawal; Ibrahim Ahmed; A Samer Al-Homsi; Mahmoud Aljurf; Joseph H Antin; Medhat Askar; Jeffery J Auletta; Vijaya Raj Bhatt; Lynette Chee; Saurabh Chhabra; Andrew Daly; Zachariah DeFilipp; James Gajewski; Robert Peter Gale; Usama Gergis; Peiman Hematti; Gerhard C Hildebrandt; William J Hogan; Yoshihiro Inamoto; Rodrigo Martino; Navneet S Majhail; David I Marks; Taiga Nishihori; Richard F Olsson; Attaphol Pawarode; Miguel Angel Diaz; Tim Prestidge; Hemalatha G Rangarajan; Olle Ringden; Ayman Saad; Bipin N Savani; Hélène Schoemans; Sachiko Seo; Kirk R Schultz; Melhem Solh; Thomas Spitzer; Jan Storek; Takanori Teshima; Leo F Verdonck; Baldeep Wirk; Jean A Yared; Jean-Yves Cahn; Daniel J Weisdorf
Journal:  J Clin Oncol       Date:  2020-05-04       Impact factor: 44.544

2.  Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Better Outcome after Umbilical Cord Blood Transplantation.

Authors:  Carmen Martínez-Losada; Carmen Martín; Rafael Gonzalez; Bárbara Manzanares; Estefania García-Torres; Concha Herrera
Journal:  Front Immunol       Date:  2017-07-13       Impact factor: 7.561

Review 3.  Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR.

Authors:  Jason Dehn; Stephen Spellman; Carolyn K Hurley; Bronwen E Shaw; Juliet N Barker; Linda J Burns; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Robert Hartzman; Martin Maiers; Susana R Marino; Carlheinz Mueller; Miguel-Angel Perales; Raja Rajalingam; Joseph Pidala
Journal:  Blood       Date:  2019-07-10       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.